The following is in a recent article from Aetna:
“Aetna will be the first national payer to waive copays for Narcan for its fully-insured commercial members – a move that will increase access and remove possible financial barriers to the lifesaving drug. In addition, Aetna will limit the quantity of opioids prescribed for acute pain and post-surgery to a seven-day supply for its commercial pharmacy members. Both changes will be effective Jan. 1, 2018.
SAE has deep knowledge across the spectrum of policy re-design, practice implementation, innovation design, monitoring and auditing, and health plan parity compliance for treatment access. We believe care should be available and adaptive to need and demand, and all stakeholders are responsible for effecting needed changes.
We keep abreast of all the pieces that have an impact on care and services addressing the opioid epidemic.
CMS announced an improved application process for section 1115(a) waivers in November.
SAE is available for technical assistance in leveraging this policy change, integrating current parity legislative requirements and treatment excellence in order to address the needs specific to your state. Call 212.684.4480 or email email@example.com to connect with our team.